Search

Your search keyword '"Huang, Weijin"' showing total 638 results

Search Constraints

Start Over You searched for: Author "Huang, Weijin" Remove constraint Author: "Huang, Weijin"
638 results on '"Huang, Weijin"'

Search Results

1. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization

13. Pseudotyped Viruses for Orthohantavirus

14. Pseudotyped Virus for Henipavirus

15. Application of Pseudotyped Viruses

16. Pseudotyped Viruses for Phlebovirus

17. Pseudotyped Viruses for the Alphavirus Chikungunya Virus

22. Analysis of monoclonal antibodies to establish a universal IVRP method suitable for identifying quadrivalent HPV vaccines that can replace in vivo efficacy tests

23. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

26. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants

27. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs

28. Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies

31. Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates

35. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

36. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

37. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2

40. Establishment of the First National Standard for Neutralizing Antibodies against SARS-CoV-2 XBB Variants

41. A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus

42. Author Response: A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus

44. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines

45. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

46. Assessing the neutralizing antibody and duration of RNA positivity from COVID-19 infected patients with immunocompromised diseases and pneumonia.

47. Optimization and validation of a virus‐like particle pseudotyped virus neutralization assay for SARS‐CoV‐2.

Catalog

Books, media, physical & digital resources